facebook button AdvanTIG-301: Ociperlimab Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Stage 3 NSCLC
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

AdvanTIG-301: Ociperlimab Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Stage 3 NSCLC

Sponsor: BeiGene, Ltd.

Protocol BGB-A317-A1217-301: Phase 3, Randomized, Open-Label Study to Compare Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A1217 Plus Concurrent Chemoradiotherapy (cCRT) Followed by Tislelizumab Plus BGB-A1217 Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Newly diagnosed, unresectable stage III non-small cell lung cancer eligible for radiation therapy.

For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly at 631-675-5075.